Turning the Promise of Genomics into the Practice of Medicine
Genomic Health is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. Genomic Health was founded in 2000 and is located in Redwood City, California.
Multigene Eexpression Tests - Diagnostic tests for cancer allowing physicians and patients to make individualized treatment decisions.
The pioneering work of Genomic Health in molecular diagnostics has led to the commercialization of two clinically validated assays (tests) that provide individualized tumor information for patients and physicians for consideration as they make important treatment decisions:
- The Oncotype DX breast cancer test is the first and only multigene expression test to be recommended by both the American Society of Clinical Oncology and the National Comprehensive Cancer Network, to predict the likelihood of chemotherapy benefit as well as recurrence, for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. Additionally, physicians use Oncotype DX to make treatment recommendations for certain node-positive breast cancer patients, and the test report also provides quantitative scores for select individual genes. Oncotype DX has been extensively evaluated in fourteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in The Journal of Clinical Oncology.
- The Oncotype DX colon cancer test is the first multigene expression test commercially available that has been clinically validated to predict risk of recurrence in patients with stage II colon cancer. For its colon cancer program, Genomic Health and its collaborators used the same rigorous clinical development strategy and standardized quantitative technology designed for the company's OncotypeDX breast cancer test. The National Surgical Adjuvant Breast and Bowel Project (NSABP) conducted three development studies and Cleveland Clinic conducted one development study, all of which were funded by Genomic Health, analyzing 761 genes from 1,851 patients with stage II colon cancer. The final set of seven recurrence and five reference genes were then independently evaluated in 1,436 stage II colon cancer patients, in the QUASAR validation study. Availability in New York is pending review by the state, as is required for all laboratory developed tests.
For detailed information about these tests, please call: (866) ONCOTYPE or visit www.oncotypedx.com
Get more information about genomics and cancer online:
Learn more about Genomic Health, a life science company.
